Frequent experimental reports confirm that the mutations in IDH1/2 are the central grounds for gliomas [9], glioblastomas [10], medulloblastomas [11], acute myeloid leukemia [12], melanoma and sporadically in melanoma [13], intrahepatic cholangiocarcinoma [14], angioimmunoblastic T cell lymphoma [15], chondrosarcoma [16], prostate cancer [17], and sporadically in thyroid, breast, stomach, and pancreatic cancers and diseases including Ollier and Maffucci syndromes [7]. This evidence concerns the gene IDH1 and glioblastoma.